Kamada (KMDA) Income from Continuing Operations (2012 - 2026)
Kamada's (KMDA) quarterly Income from Continuing Operations came in at $11.1 million in Q2 2026, up 169.15% on a YoY basis from $4.1 million in Q2 2025, and up 67.16% quarter-over-quarter from $6.6 million in Q1 2026.
Analysis
Kamada (KMDA) Income from Continuing Operations (2012 - 2026) Analysis & Trends
Kamada (KMDA) has reported Income from Continuing Operations for 15 consecutive years, with $11.1 million the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Income from Continuing Operations rose 169.15% year-over-year to $11.1 million; the trailing twelve-month figure through Jun 2026 stood at $31.1 million (up 67.86% YoY), and the FY2025 full-year result was $26.7 million, up 119.04% from the prior year.
- Income from Continuing Operations rose to $11.1 million in Q2 2026 per KMDA's latest filing, from $6.6 million in the prior quarter.
- Across five years, Income from Continuing Operations topped out at $11.1 million in Q2 2026 and bottomed at -$3.9 million in Q2 2022.
- Historically, Income from Continuing Operations has averaged $3.5 million across 5 years, with a median of $3.6 million in 2023.
- The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations tumbled 518.46% in 2022, then jumped 565.91% in 2023.
- Over 5 years, Income from Continuing Operations stood at $2.9 million in 2022, then surged by 69.5% to $5.0 million in 2023, then tumbled by 77.76% to $1.1 million in 2024, then jumped by 432.07% to $5.9 million in 2025, then jumped by 88.22% to $11.1 million in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered $11.1 million, $6.6 million, and $5.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.77 Bn | 197.79 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 181.13 Bn | 177.95 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 132.24 Bn | 124.39 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.89 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 61.56 Bn | 56.38 Bn | 1.37 Bn | 601.00 Mn |
| 6 | Moderna | 54.38 Bn | 49.24 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.44 Bn | 31.13 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.17 Bn | 29.89 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 30.12 Bn | 30.12 Bn | 1.16 Mn | -290.61 Mn |
| 10 | Kamada | 473.28 Mn | 403.14 Mn | 22.47 Mn | 11.12 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 11.12 Mn |
| Mar 31, 2026 | 6.65 Mn |
| Dec 31, 2025 | 5.91 Mn |
| Sep 30, 2025 | 7.44 Mn |
| Jun 30, 2025 | 4.13 Mn |
| Mar 31, 2025 | 9.26 Mn |
| Dec 31, 2024 | 1.11 Mn |
| Sep 30, 2024 | 4.03 Mn |
| Jun 30, 2024 | 4.55 Mn |
| Mar 31, 2024 | 2.51 Mn |
| Dec 31, 2023 | 4.99 Mn |
| Sep 30, 2023 | 3.22 Mn |
| Jun 30, 2023 | 1.81 Mn |
| Mar 31, 2023 | -1.81 Mn |
| Dec 31, 2022 | 2.94 Mn |
| Sep 30, 2022 | 484,000.00 |
| Jun 30, 2022 | -3.92 Mn |
| Mar 31, 2022 | -1.83 Mn |
| Dec 31, 2021 | -4.66 Mn |
| Sep 30, 2021 | -845,000.00 |